A reported bipartisan House proposal called the Faster Clinical Trials Act would seek to build reusable clinical-trial networks for rare and chronic diseases, potentially allowing some patients to participate through their usual medical care. CNBC reported on Oct. 22 that Representatives Jake Auchincloss, a Massachusetts Democrat, and Morgan Griffith, a Virginia Republican, were introducing the measure.
No bill text, bill number or sponsor announcement was available at publication. The reported title, sponsors, provisions, funding level, 30% target and introduction status therefore cannot be independently assessed without legislative language or an official congressional announcement.
CNBC reported that the proposal would place the Food and Drug Administration at the center of an effort to develop standing, point-of-care trial networks rather than assembling every site and process anew for each study. It would create an FDA Center for Clinical Trial Innovation, assign work to the agency’s Rare Disease Innovation Hub and direct up to $75 million annually to FDA over five years, according to CNBC.
The reported measure also sets a policy goal of reducing trial costs and enrollment time by at least 30%. That is not a demonstrated result, and without legislative language it is not possible to assess how the target would be defined, which trials would qualify, or what obligations participating health systems and researchers would have.
Bringing research closer to routine care
The model described by CNBC would allow some trial activities to happen nearer to where patients already receive care. Depending on the study, participants might receive an investigational treatment in a regular physician’s office and provide follow-up information through telehealth visits, electronic health records or wearable devices. The aim would be to reduce travel and other practical barriers to enrollment, especially for patients with uncommon disorders.
Reusable networks could preserve trained staff, data systems and procedures across studies. CNBC also reported that the proposal would encourage computer simulations in early drug development and seek to address common causes of FDA clinical-trial suspensions.
Such networks would not suit every intervention. Mark McClellan, the Duke-Margolis Institute for Health Policy director cited by CNBC, said intensive treatments such as gene therapies would still need academic medical centers. A point-of-care approach could expand options for selected parts of research without replacing specialty centers.
Rare-disease trial barriers also extend beyond enrollment. The National Institutes of Health’s clinical-trial readiness program for rare diseases identifies small patient populations, incomplete natural-history knowledge and a shortage of suitable biomarkers and clinical outcome measures as obstacles to designing, conducting and interpreting rigorous studies.
Natural-history research tracks how a disease changes without a new intervention. For many rare conditions, sparse data can make it harder to determine whether a participant’s improvement or decline reflects a treatment, the usual variation of the disease, or another factor. A biomarker or outcome measure also must reliably capture a meaningful change. Faster recruitment alone cannot resolve those scientific problems.
NIH defines a rare disease as one affecting fewer than 200,000 people in the United States. More than an estimated 10,000 rare diseases affect millions of Americans, NIH says, while effective treatments are available for about 5% of them. That figure provides broad context for unmet need, not an estimate of how many conditions the reported proposal would affect.
How the reported proposal differs from FDA’s current work
The reported measure follows an earlier congressional discussion of overlapping ideas. A May article hosted on Auchincloss’s official House website described a bipartisan draft proposal to embed trials in routine care through point-of-care networks and codify the Rare Disease Innovation Hub. That earlier account does not establish that the Faster Clinical Trials Act has the same language, funding or legislative path.
FDA is also pursuing a separate clinical-development modernization effort. On Sept. 21, the agency announced Operation TrialBlazer actions, including an Expedited Investigational New Drug Pilot Program. Under that pilot, sponsors working with qualified research institutions may submit individual components of an investigational new drug application for rolling review while FDA maintains safety and scientific oversight standards.
That FDA pilot concerns the timing and review of development submissions, particularly in early-stage work; the reported House proposal centers on durable trial-site infrastructure and participation barriers. FDA has estimated that updated information expectations for chemistry, manufacturing and controls in first-in-human Phase 1 applications could save developers six to 12 months. That estimate concerns the agency’s own early-development policy, not evidence that the reported legislation would achieve its 30% goal.
CNBC reported that Griffith did not expect a vote before the following year, while Auchincloss’s office was working with senators on a similar measure. Even if formally introduced, legislation would require committee consideration and passage in both chambers. Its practical value would depend on its final language, funding and ability to improve access while preserving the specialized oversight many trials require.
